Minaris Advanced Therapies launches as the leading global partner dedicated to cell therapy development, manufacturing, and testing
New company unveiled at the annual ISCT conference in New Orleans combines two tenured and innovative CDMOs with a testing powerhouse
PHILADELPHIA, May 7, 2025 /PRNewswire/ -- Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi Advanced Therapies have been combined to form Minaris Advanced Therapies ™, a global cell therapy CDMO and testing partner. The company is headquartered in Philadelphia, Pennsylvania.
With modern facilities approved for commercial production in the United States (Allendale, NJ and Philadelphia), Europe (Munich) and Asia-Pacific (Yokohama, Japan), Minaris Advanced Therapies manufactures clinical-stage and commercial products on three continents and has a proven track record of delivering more than 7,500 GMP batches.
The company currently manufactures two commercial cell therapies and provides testing services for more than 27 commercial products. The company's capabilities include innovative platforms, development and manufacturing capabilities for cell therapies and viral vectors, and extensive testing services. With more than 25 years of cell therapy CDMO experience and over 40 years of experience in biosafety testing and product characterization, the new company will support the next wave of commercial cell therapies.
"CDMOs supporting the cell therapy industry have struggled to evolve from a small-scale cottage industry to deliver cost effective manufacturing at scale," said Iain Baird, chairman of Minaris Advanced Therapies. "Our mission is to solve the development and manufacturing challenges preventing these promising therapies from successful worldwide commercialization."
The team includes more than 1,400 industry professionals with deep scientific and regulatory expertise. The company's testing business unit provides unrivalled expertise in analytical method development and GMP-grade biosafety and product characterization testing services for both in-house and external programs.
"Minaris Advanced Therapies is designed to help the industry treat more patients by providing the experience, global footprint, and platforms to accelerate timelines and enable commercialization," said Eytan Abraham, Ph.D., chief commercial and technology officer. "Many of the technologies needed to reduce cost of goods sold and improve turnaround time already exist, we will drive their adoption and implementation at scale."
Built for speed, scale and science
Minaris Advanced Therapies brings together:
About Minaris Advanced Therapies
Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on cell and gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 730,000 square feet of infrastructure across the United States, Europe and Asia. We have manufactured and released over 7,500 GMP batches and our global network supports therapy developers through early-stage development, clinical trials and commercial manufacturing. By combining scientific expertise with best-in-class manufacturing and testing services, we help bring safe, effective therapies to patients faster and more efficiently. Visit minaris.com to learn more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
Novogene Establishes New Subsidiary in Korea to Accelerate Multi-Omics Research
SEOUL, South Korea, June 23, 2025 /PRNewswire/ -- Novogene, a global leader in next-generation sequencing (NGS) and multi-omics solutions, today announced the establishment of Novogene Korea Limited, a wholly owned subsidiary headquartered in Seoul. This strategic expansion deepens Novogene's long-standing engagement with Korea's biomedical and biotech sectors, reinforcing its commitment to delivering rapid, high-quality, and cost-effective multi-omics services tailored to local research needs. The new entity provides localized customer support, shorter project timelines, and stronger collaboration with Korea's vibrant scientific community — spanning cancer genomics, microbiome studies, precision medicine, and agricultural genomics. Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. "South Korea is a global innovation hub, and by establishing a dedicated team in Seoul, we are investing in the future of multi-omics discovery," said Justin Lee, Vice President, Novogene Asia Pacific, Middle East & Africa (AMEA). "With the launch of Novogene Korea, we are even better positioned to support our customers with rapid, cost-effective, and reliable services that are already trusted by more than 7,300 organizations worldwide. We sincerely thank the Korean scientific community for their continued trust and collaboration in advancing the frontiers of science." Backed by robust government R&D support, world-class academic institutions, and a dynamic biotech ecosystem, South Korea is uniquely positioned to lead the next wave of genomic innovation. Novogene Korea will partner closely with universities, start-ups, and research hospitals to help unlock transformative insights in health, agriculture, and beyond. About Novogene Novogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation.
Korea Herald
an hour ago
- Korea Herald
EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds
HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are associated with significantly accelerated biological ageing and a more than threefold increase in the risk of premature death. This study is the first to show that nightmares independently predict faster biological ageing and earlier mortality – even after accounting for other health issues. Led by Dr Abidemi Otaiku of the UK Dementia Research Institute and Imperial College London, the study analysed data from 2,429 children aged 8 to 10 and 183,012 adults aged 26 to 86 across six long-term population cohorts. Nightmare frequency in adults was self-reported at the start of the study, with participants followed for up to 19 years. For children, nightmare frequency was reported by their parents at the beginning of the study. Results showed that adults reporting weekly nightmares were more than three times as likely to die prematurely (before age 70) compared to those who rarely or never experienced nightmares. Children and adults with more frequent nightmares also exhibited faster biological ageing, which accounted for approximately 40% of the heightened mortality risk. Notably, weekly nightmares were found to be a stronger predictor of premature death than other established risk factors such as smoking, obesity, poor diet, and low physical activity. "Our sleeping brains cannot distinguish dreams from reality", Dr Otaiku explained. "That's why nightmares often wake us up sweating, gasping for breath, and with our hearts pounding – because our fight-or-flight response has been triggered. This stress reaction can be even more intense than anything we experience while awake." He continued, "Nightmares lead to prolonged elevations of cortisol, a stress hormone closely linked to faster cellular ageing. For those who frequently experience nightmares, this cumulative stress may significantly impact the ageing process. Additionally, nightmares disrupt both sleep quality and duration, impairing the body's essential overnight cellular restoration and repair. The combined effects of chronic stress and disrupted sleep likely contribute to the accelerated ageing of our cells and bodies." The association between frequent nightmares and accelerated ageing remained consistent across all ages, sexes, ethnicities, and mental health statuses, indicating a universal effect. Even monthly nightmares were linked to faster ageing and increased mortality compared to rare or no nightmares, emphasising the importance of reducing nightmare frequency across the population.
Korea Herald
6 hours ago
- Korea Herald
KANEKA UBIQUINOL™ WINS COVETED MARKETING AWARD 2025 AT NATURAL HEALTH PRODUCTS NEW ZEALAND SUMMIT
SYDNEY, June 23, 2025 /PRNewswire/ -- Kaneka Corporation Supplement Division APAC, the world-renowned manufacturer and global supplier of Ubiquinol is thrilled to announce that Kaneka Ubiquinol™ has been awarded the prestigious Forbes Packaging Marketing Award 2025 at the Natural Health Products New Zealand (NHPNZ) Summit, further elevating the brand's position and stature in the natural health industry across the APAC region. The win reflects Kaneka Ubiquinol's outstanding efforts in shining the spotlight on the role of mitochondrial health powered by Ubiquinol, in supporting optimal wellbeing. The award celebrates the strategic impact, scientific credibility and executional excellence of its multi-channel marketing programs which have worked to reach, engage and build trust with brandholders, healthcare professionals, pharmacists, media and consumers alike. As a result this has helped position mitochondrial health and Ubiquinol as the new frontier of evidence-based wellbeing. Mitochondria, powered by the naturally occurring antioxidant ubiquinol, are the millions of "powerhouses" found in all cells that generate energy in our body. They are found in the largest concentrations in tissues and organs requiring the highest levels of energy production – heart, brain, liver, lungs, muscles, sperm and ovum. Science shows that from the age of approximately 30 + natural Ubiquinol levels start to decline, which may require supplementation. Kaneka Ubiquinol's unique globally patented precision yeast fermentation process enables the production of bioidentical Ubiquinol, delivering a premium, clinically proven ingredient that supports mitochondrial health. Upon receiving the award Tsuyoshi Takakuwa, Head of Marketing & Sales (APAC) Supplemental Nutrition Business Division, Kaneka Corporation, Japan said "this recognition reflects the collective efforts of our marketing, science, R&D teams, healthcare practitioner partners, brandholders, KOLs and, importantly consumers, united by a shared commitment to science, quality, education and a long-term vision to cement Ubiquinol's role as the foundation of mitochondrial health." On congratulating the team, Kazuki Takita, Oceania & Asia Marketing & Sales Team, Supplement Business Group, Supplement Strategic Unit, added that the award is a powerful testament of the success of the brand's multi-market, multi-channel strategy, which supports Kaneka Ubiquinol's presence and credibility across the APAC region. "This award illustrates our strategic vision: to position Kaneka Ubiquinol™ as a trusted ingredient for healthcare professionals, a premium asset for brandholders, and a clinically supported ingredient for consumers seeking high-quality, evidence-based supplementation to support their overall health and wellbeing," he continued. "Thank you to NHPNZ and the judging panel for this honour and we extend our congratulations to all the other finalists and winners." ABOUT KANEKA UBIQUINOL™ Kaneka Ubiquinol™ is supported by 100+ scientific studies, 80+ patents and 45+ years of research, with applications spanning mitochondrial health, cardiovascular health, cognitive function, women's health, reproductive health, energy production, sleep, stress, healthy ageing and vitality. Kaneka Ubiquinol's impeccable standards are built on the Japanese philosophy of 'Kaizen' meaning 'a commitment to quality, efficiency and pursuit of perfection', from the company's rigorous commitment to quality and research, to their outstanding stakeholder support. Its strict adherence to the highest manufacturing standards guarantees a stable ingredient, free from impurities, meeting rigorous standards and sustainability requirements, setting the global benchmark for production quality. Listed in over 50 countries in 1000+ practitioner and OTC nutraceutical brands since 2006.
